Milestone
3.2.e
Clinical trials for licensed vaccines and adjuvants
In progress
Conduct clinical trials to assess combinations of licensed seasonal influenza vaccines and vaccine components (e.g., adjuvants) to identify strategies that offer improved effectiveness against influenza.
Progress Highlights
Hegmann 2025 conducted a phase 1, randomized, double-blind trial among 241 healthy adults 18-45 years of age to evaluate the effects of two newer adjuvants, AF03 (a squalene-based oil-in-water emulsion) or Advax-CpG55.2 (a novel combination adjuvant), used in combination with two different licensed QIVs, Fluzone and Flublok. Results showed that both QIVs were safe and well tolerated when combined with either adjuvant and that there were no significant differences between the immunogenicity elicited by the two adjuvants.